About Kindred Biosciences (NASDAQ:KIN)
Kindred Biosciences, Inc. is a development-stage biopharmaceutical company. The Company is focused on developing therapies for pets. The Company's product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Company is developing product candidates for over 20 indications and focused on small molecule products and canine and feline biologics products. The Company is developing antibodies that targets canine Interleukin 17A (IL-17a), Interleukin 4A (IL-4Ra), Interleukin 3 (IL-3), CD-20, Immunoglobulin E (IgE), tumor necrosis factors (TNF) and other validated targets. The Company's lead product candidates are Zimeta, which is indicated for the treatment of fever in horses, and KIND-010 for management of weight loss in cats. The Company's other product candidates include KIND-010, KIND-014, KIND-015, KIND-510, KIND-502, KIND-0888, KIND-509, and several antibodies that target cytokines involved in atopic dermatitis.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:KIN
CUSIPN/A
Phone650-701-7901
Debt
Debt-to-Equity RatioN/A
Current Ratio13.59%
Quick Ratio13.59%
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$3.00 per share
Price / Book3.02
Profitability
EPS (Most Recent Fiscal Year)($1.23)
Net Income$-30,870,000.00
Net MarginsN/A
Return on Equity-38.00%
Return on Assets-36.29%
Miscellaneous
Employees63
Outstanding Shares28,190,000
Kindred Biosciences (NASDAQ:KIN) Frequently Asked Questions
What is Kindred Biosciences' stock symbol?
Kindred Biosciences trades on the NASDAQ under the ticker symbol "KIN."
How were Kindred Biosciences' earnings last quarter?
Kindred Biosciences (NASDAQ:KIN) posted its earnings results on Thursday, March, 1st. The biopharmaceutical company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.33) by $0.02. View Kindred Biosciences' Earnings History.
When is Kindred Biosciences' next earnings date?
What price target have analysts set for KIN?
6 brokers have issued 12-month price objectives for Kindred Biosciences' stock. Their forecasts range from $8.00 to $11.00. On average, they anticipate Kindred Biosciences' share price to reach $10.10 in the next twelve months. View Analyst Ratings for Kindred Biosciences.
Who are some of Kindred Biosciences' key competitors?
Some companies that are related to Kindred Biosciences include Biohaven Pharmaceutical (BHVN), Athenex (ATNX), CytomX Therapeutics (CTMX), Zai Lab (ZLAB), Uniqure (QURE), MacroGenics (MGNX), Access Pharmaceuticals (ABEO), Alder BioPharmaceuticals (ALDR), Flexion Therapeutics (FLXN), Amphastar Pharmaceuticals (AMPH), Assembly Biosciences (ASMB), Inflarx (IFRX), Lexicon Pharmaceuticals (LXRX), Amarin (AMRN) and Mirati Therapeutics (MRTX).
Who are Kindred Biosciences' key executives?
Kindred Biosciences' management team includes the folowing people:
- Wendy Wee, Chief Financial Officer (Age 64)
- Denise M. Bevers, Chief Operating Officer, Secretary (Age 47)
- Hangjun Zhan, Chief Scientific Officer
- Herbert D. Montgomery, Independent Director (Age 68)
- Raymond Townsend, Independent Director (Age 70)
- Ervin Veszpremi, Independent Director (Age 56)
Has Kindred Biosciences been receiving favorable news coverage?
Headlines about KIN stock have trended somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies positive and negative press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Kindred Biosciences earned a news impact score of 0.08 on Accern's scale. They also gave press coverage about the biopharmaceutical company an impact score of 46.53 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near future.
How do I buy shares of Kindred Biosciences?
Shares of KIN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Kindred Biosciences' stock price today?
One share of KIN stock can currently be purchased for approximately $9.05.
How big of a company is Kindred Biosciences?
Kindred Biosciences has a market capitalization of $257.93 million. The biopharmaceutical company earns $-30,870,000.00 in net income (profit) each year or ($1.23) on an earnings per share basis. Kindred Biosciences employs 63 workers across the globe.
How can I contact Kindred Biosciences?
Kindred Biosciences' mailing address is 1555 BAYSHORE HIGHWAY SUITE 200, BURLINGAME CA, 94010. The biopharmaceutical company can be reached via phone at 650-701-7901 or via email at [email protected]
MarketBeat Community Rating for Kindred Biosciences (KIN)
MarketBeat's community ratings are surveys of what our community members think about Kindred Biosciences and other stocks. Vote "Outperform" if you believe KIN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KIN will underperform the S&P 500 over the long term. You may vote once every thirty days.
Kindred Biosciences (NASDAQ:KIN) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
6 Wall Street analysts have issued ratings and price targets for Kindred Biosciences in the last 12 months. Their average twelve-month price target is $10.10, suggesting that the stock has a possible upside of 11.60%. The high price target for KIN is $11.00 and the low price target for KIN is $8.00. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.67 | 2.67 | 2.67 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
1 Strong Buy Rating(s) |
| Consensus Price Target: | $10.10 | $10.10 | $9.90 | $9.00 |
| Price Target Upside: | 11.60% upside | 13.48% upside | 3.13% upside | 29.50% upside |
Kindred Biosciences (NASDAQ:KIN) Consensus Price Target History
Kindred Biosciences (NASDAQ:KIN) Analyst Ratings History
Show:
(Data available from 4/25/2016 forward)
Kindred Biosciences (NASDAQ:KIN) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Kindred Biosciences (NASDAQ KIN) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 19.10%
Institutional Ownership Percentage: 64.36%
Kindred Biosciences (NASDAQ KIN) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/2/2018 | Richard Chin | Insider | Sell | 20,000 | $8.39 | $167,800.00 | 2,266,071 |  |
| 3/16/2018 | Raymond Townsend | Director | Sell | 2,670 | $9.45 | $25,231.50 | 25,057 | |
| 3/12/2018 | Raymond Townsend | Director | Sell | 91 | $9.45 | $859.95 | 23,233 | |
| 1/2/2018 | Raymond Townsend | Director | Sell | 6,419 | $9.45 | $60,659.55 | 18,419 | |
| 7/12/2017 | Park West Asset Management Llc | Major Shareholder | Buy | 600,000 | $7.50 | $4,500,000.00 | | |
| 7/3/2017 | Richard Chin | Insider | Sell | 13,000 | $8.26 | $107,380.00 | 2,297,546 | |
| 6/22/2017 | Richard Chin | Insider | Sell | 13,000 | $7.75 | $100,750.00 | 2,310,546 | |
| 6/8/2017 | Park West Asset Management Llc | Major Shareholder | Buy | 15,311 | $6.65 | $101,818.15 | | |
| 5/11/2017 | Park West Asset Management Llc | Major Shareholder | Buy | 155,076 | $6.83 | $1,059,169.08 | | |
| 3/15/2017 | Park West Asset Management Llc | Major Shareholder | Buy | 400,000 | $6.60 | $2,640,000.00 | | |
| 3/13/2017 | Park West Asset Management Llc | Major Shareholder | Buy | 4,200 | $6.20 | $26,040.00 | | |
| 3/9/2017 | Park West Asset Management Llc | Major Shareholder | Buy | 18,066 | $6.08 | $109,841.28 | | |
| 1/13/2017 | Park West Asset Management Llc | Major Shareholder | Buy | 1,690,000 | $6.20 | $10,478,000.00 | | |
| 1/9/2017 | Park West Asset Management Llc | Major Shareholder | Buy | 131,500 | $5.30 | $696,950.00 | | |
| 1/6/2017 | Park West Asset Management Llc | Major Shareholder | Buy | 110,617 | $5.10 | $564,146.70 | | |
| 12/16/2016 | Park West Asset Management Llc | Insider | Sell | 18,000 | $4.78 | $86,040.00 | | |
| 12/14/2016 | Park West Asset Management Llc | Major Shareholder | Buy | 8,334 | $4.75 | $39,586.50 | | |
| 12/13/2016 | Park West Asset Management Llc | Major Shareholder | Buy | 1,148 | $4.75 | $5,453.00 | | |
| 12/12/2016 | Park West Asset Management Llc | Major Shareholder | Buy | 3,112 | $4.74 | $14,750.88 | | |
| 3/15/2016 | Ernest Mario | Director | Buy | 30,000 | $3.55 | $106,500.00 | 99,583 | |
| 11/23/2015 | Raymond Townsend | Director | Buy | 2,000 | $4.00 | $8,000.00 | 12,000 | |
| 11/18/2015 | Raymond Townsend | Director | Buy | 2,323 | $4.78 | $11,103.94 | 10,000 | |
| 8/31/2015 | Raymond Townsend | Director | Buy | 1,677 | $5.85 | $9,810.45 | 7,677 | |
| 8/14/2015 | Raymond Townsend | Director | Buy | 3,000 | $6.04 | $18,120.00 | | |
| 9/29/2014 | Oleg Nodelman | Director | Buy | 100,000 | $9.56 | $956,000.00 | | |
| 9/3/2014 | Ernest Mario | Director | Buy | 10,000 | $10.55 | $105,500.00 | | |
| 8/28/2014 | Oleg Nodelman | Director | Buy | 47,000 | $10.85 | $509,950.00 | | |
| 8/26/2014 | Oleg Nodelman | Director | Buy | 85,244 | $10.50 | $895,062.00 | | |
| 12/12/2013 | Kevin Schultz | Insider | Buy | 4,000 | $7.00 | $28,000.00 | | |
| 12/12/2013 | Oleg Nodelman | Director | Buy | 400,000 | $7.00 | $2,800,000.00 | | |
| 12/12/2013 | Stephen Sundlof | SVP | Buy | 1,000 | $7.00 | $7,000.00 | | |
(Data available from 1/1/2013 forward)
Kindred Biosciences (NASDAQ KIN) News Headlines
| Source: |
|
Kindred Biosciences (NASDAQ:KIN) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Kindred Biosciences (NASDAQ:KIN) Income Statement, Balance Sheet and Cash Flow Statement
Kindred Biosciences (NASDAQ KIN) Stock Chart for Wednesday, April, 25, 2018
Loading chart…
